<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article" xml:lang="EN"><front><journal-meta><journal-id journal-id-type="nlm-ta">Int J Chron Obstruct Pulmon Dis</journal-id><journal-id journal-id-type="publisher-id">International Journal of COPD</journal-id><journal-title>International Journal of Chronic Obstructive Pulmonary Disease</journal-title><issn pub-type="ppub">1176-9106</issn><issn pub-type="epub">1178-2005</issn><publisher><publisher-name>Dove Medical Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">18488437</article-id><article-id pub-id-type="pmc">2528215</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Research</subject></subj-group></article-categories><title-group><article-title>Effect of add-on therapy of tiotropium in COPD treated with theophylline</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Kawayama</surname><given-names>Tomotaka</given-names></name><xref ref-type="aff" rid="au1">1</xref></contrib><contrib contrib-type="author"><name><surname>Hoshino</surname><given-names>Tomoaki</given-names></name><xref ref-type="aff" rid="au1">1</xref></contrib><contrib contrib-type="author"><name><surname>Ichiki</surname><given-names>Masao</given-names></name><xref ref-type="aff" rid="au2">2</xref></contrib><contrib contrib-type="author"><name><surname>Tsuda</surname><given-names>Toru</given-names></name><xref ref-type="aff" rid="au3">3</xref></contrib><contrib contrib-type="author"><name><surname>Kinoshita</surname><given-names>Masaharu</given-names></name><xref ref-type="aff" rid="au4">4</xref></contrib><contrib contrib-type="author"><name><surname>Takata</surname><given-names>Shohei</given-names></name><xref ref-type="aff" rid="au5">5</xref></contrib><contrib contrib-type="author"><name><surname>Koga</surname><given-names>Takeharu</given-names></name><xref ref-type="aff" rid="au1">1</xref></contrib><contrib contrib-type="author"><name><surname>Iwanaga</surname><given-names>Tomoaki</given-names></name><xref ref-type="aff" rid="au1">1</xref></contrib><contrib contrib-type="author"><name><surname>Aizawa</surname><given-names>Hisamichi</given-names></name><xref ref-type="aff" rid="au1">1</xref></contrib><contrib contrib-type="author"><collab>Kurume COPD Study Group</collab><xref rid="fn2" ref-type="fn">*</xref></contrib></contrib-group><aff id="au1"><label>1</label><institution>Department of Medicine, Kurume University School of Medicine</institution><addr-line>Kurume, Japan</addr-line></aff><aff id="au2"><label>2</label><institution>Division of Respiratory Medicine, National Hospital Organization Kyushu Medical Center</institution><addr-line>Fukuoka, Japan</addr-line></aff><aff id="au3"><label>3</label><institution>Tsuda Hospital</institution><addr-line>Kitakyushu, Japan</addr-line></aff><aff id="au4"><label>4</label><institution>Nagata Hospital</institution><addr-line>Yanagawa, Japan</addr-line></aff><aff id="au5"><label>5</label><institution>National Hospital Organization Fukuoka-Higashi Medical Center</institution><addr-line>Fukuoka, Japan</addr-line></aff><author-notes><corresp id="fn1">Correspondence: Hisamichi Aizawa Department of Medicine, Kurume University School of Medicine, 67 Asahimachi, Kurume 830-0011, Japan Tel +81 942 31 7560 Fax +81 942 31 7703 Email <email>aizawa@med.kurume-u.ac.jp</email></corresp></author-notes><pub-date pub-type="ppub"><month>3</month><year>2008</year></pub-date><pub-date pub-type="epub"><month>3</month><year>2008</year></pub-date><volume>3</volume><issue>1</issue><fpage>137</fpage><lpage>147</lpage><copyright-statement>© 2008 Kawayama et al, publisher and licensee Dove Medical Press Ltd.</copyright-statement><copyright-year>2008</copyright-year><abstract><sec><title><offsets xml_i="3881" xml_f="3891" txt_i="11" txt_f="21">Background</offsets></title><p><offsets xml_i="3902" xml_f="4117" txt_i="22" txt_f="237">Although combination therapy with bronchodilators is recommended for chronic obstructive pulmonary disease (COPD), there is insufficient evidence for the efficacy of some combinations of long-acting bronchodilators.</offsets></p></sec><sec><title><offsets xml_i="4139" xml_f="4148" txt_i="239" txt_f="248">Objective</offsets></title><p><offsets xml_i="4159" xml_f="4262" txt_i="249" txt_f="352">We investigated the effects of a combination therapy with tiotropium and theophylline in COPD patients.</offsets></p></sec><sec sec-type="methods"><title><offsets xml_i="4303" xml_f="4310" txt_i="354" txt_f="361">Methods</offsets></title><p><offsets xml_i="4321" xml_f="4549" txt_i="362" txt_f="590">In a 12-week, open-labeled, parallel-group randomized study, pulmonary functions and dyspnea scores were compared between the combination and theophylline alone therapy at baseline, and 4 and 8 weeks after randomization in COPD.</offsets></p></sec><sec><title><offsets xml_i="4571" xml_f="4578" txt_i="592" txt_f="599">Results</offsets></title><p><offsets xml_i="4589" xml_f="4780" txt_i="600" txt_f="791">Sixty-one COPD patients completed the trial (31 combination therapy, 30 theophylline alone; mean age 70 years; 58 males; mean dyspnea score 2.0 and forced expiratory volume in one second (FEV</offsets><sub><offsets xml_i="4785" xml_f="4786" txt_i="791" txt_f="792">1</offsets></sub><offsets xml_i="4792" xml_f="4823" txt_i="792" txt_f="823">) 1.5 L [62.5% predicted]). FEV</offsets><sub><offsets xml_i="4828" xml_f="4829" txt_i="823" txt_f="824">1</offsets></sub><offsets xml_i="4835" xml_f="5366" txt_i="824" txt_f="1343"> in the combination group, but not in the theophylline alone, was significantly increased at 4 (1.56 ± 0.13 L, p &lt; 0.001) and 8 weeks (1.60 ± 0.13 L, p &lt; 0.001) from the baseline (1.40 ± 0.12 L). In the combination group, but not the theophylline alone group, the dyspnea score was significantly improved after 4 (p &lt; 0.01) and 8 weeks (p &lt; 0.05) compared with baseline. In 17 patients who did not receive theophylline at screening, treatment with 4 or 8 weeks of theophylline alone did not improve dyspnea score or FEV</offsets><sub><offsets xml_i="5371" xml_f="5372" txt_i="1343" txt_f="1344">1</offsets></sub><offsets xml_i="5378" xml_f="5379" txt_i="1344" txt_f="1345">.</offsets></p></sec><sec><title><offsets xml_i="5401" xml_f="5411" txt_i="1347" txt_f="1357">Conclusion</offsets></title><p><offsets xml_i="5422" xml_f="5734" txt_i="1358" txt_f="1670">Addition of tiotropium therapy to theophylline treatment can improve dyspnea and pulmonary function in COPD. Although this study did not assess whether there was any benefit of adding theophylline to patients treated with tiotropium, tiotropium can be a useful addition in COPD already treated with theophylline.</offsets></p></sec></abstract><kwd-group><kwd>chronic obstructive pulmonary disease</kwd><kwd>long acting anticholinergics agent</kwd><kwd>tiotropium</kwd><kwd>slow release theophylline</kwd><kwd>combination therapy</kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><title><offsets xml_i="6016" xml_f="6028" txt_i="1679" txt_f="1691">Introduction</offsets></title><p><offsets xml_i="6039" xml_f="6257" txt_i="1692" txt_f="1910">Chronic obstructive pulmonary disease (COPD) is characterized by progressive airway obstruction, chronic respiratory symptoms, and impaired health status, and it is a leading cause of morbidity and morality worldwide (</offsets><xref ref-type="bibr" rid="b17"><offsets xml_i="6289" xml_f="6298" txt_i="1910" txt_f="1919">Gold 2006</offsets></xref><offsets xml_i="6305" xml_f="6705" txt_i="1919" txt_f="2319">). COPD is treatable, and pharmacological treatment is effective in controlling symptoms and health status. In particular, the use of bronchodilators plays a central role in the pharmacological treatment of symptomatic COPD patients. Bronchodilators improve airway obstruction, symptom control, health status, and health-related quality of life (QOL), and they reduce the frequency of exacerbations (</offsets><xref ref-type="bibr" rid="b15"><offsets xml_i="6737" xml_f="6749" txt_i="2319" txt_f="2331">Donohue 2005</offsets></xref><offsets xml_i="6756" xml_f="6758" txt_i="2331" txt_f="2333">; </offsets><xref ref-type="bibr" rid="b17"><offsets xml_i="6790" xml_f="6799" txt_i="2333" txt_f="2342">Gold 2006</offsets></xref><offsets xml_i="6806" xml_f="6808" txt_i="2342" txt_f="2344">).</offsets></p><p><offsets xml_i="6815" xml_f="6926" txt_i="2345" txt_f="2456">Tiotropium bromide is a long-acting anticholinergic that provides sustained bronchodilation through prolonged M</offsets><sub><offsets xml_i="6931" xml_f="6932" txt_i="2456" txt_f="2457">3</offsets></sub><offsets xml_i="6938" xml_f="6969" txt_i="2457" txt_f="2488"> muscarinic receptor blockade (</offsets><xref ref-type="bibr" rid="b14"><offsets xml_i="7001" xml_f="7017" txt_i="2488" txt_f="2504">Disse et al 1999</offsets></xref><offsets xml_i="7024" xml_f="7229" txt_i="2504" txt_f="2709">). Previous studies have shown that inhaled tiotropium improves pulmonary function, dyspnea, and QOL in COPD to a significantly greater extent than placebo or the short-acting anticholinergic ipratropium (</offsets><xref ref-type="bibr" rid="b8"><offsets xml_i="7260" xml_f="7279" txt_i="2709" txt_f="2728">Casaburi et al 2002</offsets></xref><offsets xml_i="7286" xml_f="7288" txt_i="2728" txt_f="2730">; </offsets><xref ref-type="bibr" rid="b40"><offsets xml_i="7320" xml_f="7338" txt_i="2730" txt_f="2748">Vincken et al 2002</offsets></xref><offsets xml_i="7345" xml_f="7494" txt_i="2748" txt_f="2897">). Tiotropium also reduces COPD exacerbations and may reduce related utilization of health-care facilities in patients with moderate to severe COPD (</offsets><xref ref-type="bibr" rid="b32"><offsets xml_i="7526" xml_f="7547" txt_i="2897" txt_f="2918">Niewoehner et al 2005</offsets></xref><offsets xml_i="7554" xml_f="7556" txt_i="2918" txt_f="2920">; </offsets><xref ref-type="bibr" rid="b16"><offsets xml_i="7588" xml_f="7605" txt_i="2920" txt_f="2937">Dusser et al 2006</offsets></xref><offsets xml_i="7612" xml_f="7815" txt_i="2937" txt_f="3140">). Furthermore, one recent study based on a retrospective 1-year analysis has raised the possibility that tiotropium is associated with a reduced rate of loss of forced expiratory volume in 1 second (FEV</offsets><sub><offsets xml_i="7820" xml_f="7821" txt_i="3140" txt_f="3141">1</offsets></sub><offsets xml_i="7827" xml_f="7830" txt_i="3141" txt_f="3144">) (</offsets><xref ref-type="bibr" rid="b2"><offsets xml_i="7861" xml_f="7879" txt_i="3144" txt_f="3162">Anzueto et al 2005</offsets></xref><offsets xml_i="7886" xml_f="7888" txt_i="3162" txt_f="3164">).</offsets></p><p><offsets xml_i="7895" xml_f="7973" txt_i="3165" txt_f="3243">Oral slow-released theophylline is used widely as a bronchodilator worldwide (</offsets><xref ref-type="bibr" rid="b38"><offsets xml_i="8005" xml_f="8024" txt_i="3243" txt_f="3262">Turner-Warwick 1957</offsets></xref><offsets xml_i="8031" xml_f="8033" txt_i="3262" txt_f="3264">; </offsets><xref ref-type="bibr" rid="b25"><offsets xml_i="8065" xml_f="8083" txt_i="3264" txt_f="3282">Jackson et al 1964</offsets></xref><offsets xml_i="8090" xml_f="8092" txt_i="3282" txt_f="3284">; </offsets><xref ref-type="bibr" rid="b29"><offsets xml_i="8124" xml_f="8148" txt_i="3284" txt_f="3308">Mitenko and Ogilvie 1973</offsets></xref><offsets xml_i="8155" xml_f="8311" txt_i="3308" txt_f="3464">). Previous studies have reported that long-term theophylline use for COPD results in improvement of pulmonary functions, including vital capacity (VC), FEV</offsets><sub><offsets xml_i="8316" xml_f="8317" txt_i="3464" txt_f="3465">1</offsets></sub><offsets xml_i="8323" xml_f="8363" txt_i="3465" txt_f="3505">, minute ventilation, and gas exchange (</offsets><xref ref-type="bibr" rid="b31"><offsets xml_i="8395" xml_f="8414" txt_i="3505" txt_f="3524">Murciano et al 1989</offsets></xref><offsets xml_i="8421" xml_f="8497" txt_i="3524" txt_f="3600">). Theophylline also has a beneficial effect on exercise endurance in COPD (</offsets><xref ref-type="bibr" rid="b19"><offsets xml_i="8529" xml_f="8546" txt_i="3600" txt_f="3617">Guyatt et al 1987</offsets></xref><offsets xml_i="8553" xml_f="8704" txt_i="3617" txt_f="3768">). Recent studies have shown that theophylline reduces the numbers of neutrophils and concentrations of interleukin-8 in the airways of COPD patients (</offsets><xref ref-type="bibr" rid="b12"><offsets xml_i="8736" xml_f="8754" txt_i="3768" txt_f="3786">Culpitt et al 2002</offsets></xref><offsets xml_i="8761" xml_f="8868" txt_i="3786" txt_f="3893">). Low-dose theophylline can also prevent oxidative stress, and it restores corticosteroid responsiveness (</offsets><xref ref-type="bibr" rid="b24"><offsets xml_i="8900" xml_f="8914" txt_i="3893" txt_f="3907">Ito et al 2002</offsets></xref><offsets xml_i="8921" xml_f="9025" txt_i="3907" txt_f="4011">). These results suggest that theophylline has anti-inflammatory effects in COPD, as it does in asthma (</offsets><xref ref-type="bibr" rid="b35"><offsets xml_i="9057" xml_f="9076" txt_i="4011" txt_f="4030">Sullivan et al 1994</offsets></xref><offsets xml_i="9083" xml_f="9085" txt_i="4030" txt_f="4032">).</offsets></p><p><offsets xml_i="9092" xml_f="9283" txt_i="4033" txt_f="4224">The GOLD (Global Initiative for Chronic Obstructive Lung Disease) guidelines recommend combination therapy with different potential bronchodilators for the pharmacological treatment of COPD (</offsets><xref ref-type="bibr" rid="b17"><offsets xml_i="9315" xml_f="9324" txt_i="4224" txt_f="4233">Gold 2006</offsets></xref><offsets xml_i="9331" xml_f="9459" txt_i="4233" txt_f="4361">). Theophylline has an additional effect in the clinical improvement of COPD when it is used in combination with a long-acting β</offsets><sub><offsets xml_i="9464" xml_f="9465" txt_i="4361" txt_f="4362">2</offsets></sub><offsets xml_i="9471" xml_f="9488" txt_i="4362" txt_f="4379">-agonist (LABA) (</offsets><xref ref-type="bibr" rid="b41"><offsets xml_i="9520" xml_f="9540" txt_i="4379" txt_f="4399">Zuwallack et al 2001</offsets></xref><offsets xml_i="9547" xml_f="9822" txt_i="4399" txt_f="4674">). However, few investigations have reported the efficacy of combination therapy with inhalation of the long-acting anticholinergic tiotropium and oral administration of slow-release theophylline in COPD patients. In Japan, theophylline is prescribed for most COPD patients (</offsets><xref ref-type="bibr" rid="b23"><offsets xml_i="9854" xml_f="9873" txt_i="4674" txt_f="4693">Ichinose et al 2006</offsets></xref><offsets xml_i="9880" xml_f="10017" txt_i="4693" txt_f="4830">). Our purpose was to investigate the efficacy and safety of add-on treatment with tiotropium in COPD patients treated with theophylline.</offsets></p></sec><sec sec-type="materials|methods"><title><offsets xml_i="10068" xml_f="10088" txt_i="4832" txt_f="4852">Material and methods</offsets></title><p><offsets xml_i="10099" xml_f="10444" txt_i="4853" txt_f="5198">The study was performed at Kurume University Hospital and at each medical institute of the Kurume COPD Study Group. The protocol was designed in accordance with good clinical practice and the latest revisions to the Declaration of Helsinki, and was approved by the institutional ethics committees of Kurume University and each medical institute.</offsets></p><sec><title><offsets xml_i="10460" xml_f="10468" txt_i="5199" txt_f="5207">Subjects</offsets></title><p><offsets xml_i="10479" xml_f="10889" txt_i="5208" txt_f="5618">COPD patients ≥40 years old and with a cigarette smoking history of ≥10 pack-years and respiratory symptoms related to COPD were enrolled in the study. All patients were diagnosed on the basis of clinical history, physical examination, chest X-ray, chest computed tomography, and pulmonary function tests, in accordance with the clinical criteria for the diagnosis and severity of COPD by the GOLD guidelines (</offsets><xref ref-type="bibr" rid="b17"><offsets xml_i="10921" xml_f="10930" txt_i="5618" txt_f="5627">Gold 2006</offsets></xref><offsets xml_i="10937" xml_f="11029" txt_i="5627" txt_f="5716">). Patients with a history of asthma, atopy, absolute peripheral eosinophil count &gt;600 mm</offsets><sup><offsets xml_i="11034" xml_f="11035" txt_i="5716" txt_f="5717">3</offsets></sup><offsets xml_i="11041" xml_f="11070" txt_i="5717" txt_f="5746">, and/or reversibility of FEV</offsets><sub><offsets xml_i="11075" xml_f="11076" txt_i="5746" txt_f="5747">1</offsets></sub><offsets xml_i="11082" xml_f="11809" txt_i="5747" txt_f="6468"> by &gt;200 mL and &gt;12% after inhalation of 200 μg salbutamol were carefully excluded. Patients who had a history of renal failure, moderate to severe prostatic hypertrophy or bladder-neck obstruction, narrow-angle glaucoma, heart failure, arrhythmia, bronchiectasis, pneumoconiosis, old mycobacterial infections, interstitial pneumonia, mental disorders, lung surgery, or any malignancies were also excluded. Five patients (16.6%) in the theophylline alone group and two patients (6.5%) in the combination group were being treated with inhaled corticosteroids at the screening visit. There was no significant difference of number between the two groups (p = 0.2554). Written informed consent was obtained from all patients.</offsets></p></sec><sec><title><offsets xml_i="11831" xml_f="11843" txt_i="6470" txt_f="6482">Study design</offsets></title><p><offsets xml_i="11854" xml_f="12149" txt_i="6483" txt_f="6778">The study was performed over a 12-week period. We used an open-labeled, parallel-group, randomized design to compare the efficacy and safety of the addition of 18 μg inhaled tiotropium once daily to theophylline in stable COPD patients. The primary end-point for this study was the change in FEV</offsets><sub><offsets xml_i="12154" xml_f="12155" txt_i="6778" txt_f="6779">1</offsets></sub><offsets xml_i="12161" xml_f="12338" txt_i="6779" txt_f="6956"> from baseline to the end of 8 weeks after treatment, and the secondary end-points were the British MRC (Medical Research Council) dyspnea scale and forced vital capacity (FVC).</offsets></p><p><offsets xml_i="12345" xml_f="12802" txt_i="6957" txt_f="7414">At the first visit, each patient underwent recording of medical, occupational, and smoking history; physical examination; chest radiography, including high-resolution computed tomography; electrocardiogram; blood testing; and spirometry as screening tests to ensure that they met the inclusion criteria. The spirometry was performed before and after inhalation of a bronchodilator at the first visit. Dyspnea was scored using the British MRC dyspnea scale (</offsets><xref ref-type="bibr" rid="b30"><offsets xml_i="12834" xml_f="12853" txt_i="7414" txt_f="7433">Moor-Jankowski 1976</offsets></xref><offsets xml_i="12860" xml_f="13254" txt_i="7433" txt_f="7827">). Patients who met all the criteria were enrolled and given 200 mg theophylline twice daily for 4 weeks (a run-in period). The patients had been receiving different doses of theophylline, or none, before the run-in period. In those patients who had been receiving higher doses, the dose was reduced to 200 mg twice daily, as reported in previous studies, to prevent high serum concentrations (</offsets><xref ref-type="bibr" rid="b27"><offsets xml_i="13286" xml_f="13296" txt_i="7827" txt_f="7837">Kelly 1987</offsets></xref><offsets xml_i="13303" xml_f="13305" txt_i="7837" txt_f="7839">; </offsets><xref ref-type="bibr" rid="b4"><offsets xml_i="13336" xml_f="13347" txt_i="7839" txt_f="7850">Barnes 1997</offsets></xref><offsets xml_i="13354" xml_f="13735" txt_i="7850" txt_f="8231">). None of the patients was treated with anti-histamines, anti-leukotrienes, cromolyn, β-blockers, ACE inhibitors, oral prednisolone, and/or LABAs during the study. Some of the patients had discontinued these medications at least 4 weeks before enrollment. Patients were excluded if they had experienced an exacerbation within 4 weeks before enrollment. The use of a short-acting β</offsets><sub><offsets xml_i="13740" xml_f="13741" txt_i="8231" txt_f="8232">2</offsets></sub><offsets xml_i="13747" xml_f="13812" txt_i="8232" txt_f="8297">-agonist or short-acting anticholinergic on demand was permitted.</offsets></p><p><offsets xml_i="13819" xml_f="14366" txt_i="8298" txt_f="8845">Following a 4-week run-in period (the end of which was defined as the baseline), patients were randomized to two groups. In one group, 18 μg of tiotropium was added on once daily from 6:00 to 8:00 am (combination group), and the other continued with the theophylline alone (theophylline alone group) for 8 weeks (the end of the treatment period). Patients who developed emesis or anorexia associated with the theophylline were withdrawn from the study. Smoking status and participation in rehabilitation programs were not altered during the trial.</offsets></p><p><offsets xml_i="14373" xml_f="14828" txt_i="8846" txt_f="9301">Physical examinations, spirometry, and blood testing, including the monitoring of plasma concentrations of theophylline and MRC scoring, were performed at screening and baseline, and after 4 and 8 weeks of treatment. Spirometry was performed at least three times between 11:00 am and noon, and the best dataset was accepted. On the basis of the results of a previous study, these values were regarded as the near-peak changes after tiotropium inhalation (</offsets><xref ref-type="bibr" rid="b14"><offsets xml_i="14860" xml_f="14876" txt_i="9301" txt_f="9317">Disse et al 1999</offsets></xref><offsets xml_i="14883" xml_f="14934" txt_i="9317" txt_f="9368">). Adverse events were evaluated during the study (</offsets><xref ref-type="fig" rid="fig1"><offsets xml_i="14966" xml_f="14974" txt_i="9368" txt_f="9376">Figure 1</offsets></xref><offsets xml_i="14981" xml_f="14983" txt_i="9376" txt_f="9378">).</offsets></p><fig id="fig1" position="float"><label><offsets xml_i="15026" xml_f="15034" txt_i="9379" txt_f="9387">Figure 1</offsets></label><caption><p><offsets xml_i="15054" xml_f="15067" txt_i="9387" txt_f="9400">Study design.</offsets></p><p><bold><offsets xml_i="15080" xml_f="15086" txt_i="9401" txt_f="9407">Notes:</offsets></bold><offsets xml_i="15093" xml_f="15094" txt_i="9407" txt_f="9408"> </offsets><sup><offsets xml_i="15099" xml_f="15100" txt_i="9408" txt_f="9409">†</offsets></sup><offsets xml_i="15106" xml_f="15196" txt_i="9409" txt_f="9499">British Medical Research Council score. Combination therapy: theophylline with tiotropium.</offsets></p></caption><graphic xlink:href="copd0301-137-01"></graphic></fig><p><offsets xml_i="15267" xml_f="15482" txt_i="9500" txt_f="9715">Data on exacerbations of COPD were also collected throughout the trial. Information on exacerbation was obtained by direct questioning of each patient. Exacerbation was defined in accordance with the description by </offsets><xref ref-type="bibr" rid="b34"><offsets xml_i="15514" xml_f="15537" txt_i="9715" txt_f="9738">Rodrignez-Roisin (2000)</offsets></xref><offsets xml_i="15544" xml_f="15545" txt_i="9738" txt_f="9739">.</offsets></p></sec><sec><title><offsets xml_i="15567" xml_f="15587" txt_i="9741" txt_f="9761">Statistical analysis</offsets></title><p><offsets xml_i="15598" xml_f="15680" txt_i="9762" txt_f="9844">The number of subjects completing the study to the stage of primary end-point (FEV</offsets><sub><offsets xml_i="15685" xml_f="15686" txt_i="9844" txt_f="9845">1</offsets></sub><offsets xml_i="15692" xml_f="15849" txt_i="9845" txt_f="10002">) testing was 61, the experiment had 90% validity at the 5% significance level in detecting differences between treatments, as reported in previous studies (</offsets><xref ref-type="bibr" rid="b21"><offsets xml_i="15881" xml_f="15898" txt_i="10002" txt_f="10019">Hirata et al 2003</offsets></xref><offsets xml_i="15905" xml_f="15907" txt_i="10019" txt_f="10021">; </offsets><xref ref-type="bibr" rid="b22"><offsets xml_i="15939" xml_f="15958" txt_i="10021" txt_f="10040">Ichinose et al 2003</offsets></xref><offsets xml_i="15965" xml_f="15967" txt_i="10040" txt_f="10042">).</offsets></p><p><offsets xml_i="15974" xml_f="16524" txt_i="10043" txt_f="10593">Demographic data and MRC score were expressed as mean ± SD. Comparisons in the demographic characteristics of patients with COPD between the combination and theophylline alone groups were analyzed by Fisher’s exact test. All data on spirometry and the time course of percentage change in pulmonary function since the screening visit were expressed as means ± SEM. Mean percentage changes between baseline (end of the run-in period) and after 4 and 8 weeks of treatment (treatment period) in each group were calculated and then compared. The unpaired </offsets><italic><offsets xml_i="16532" xml_f="16533" txt_i="10593" txt_f="10594">t</offsets></italic><offsets xml_i="16542" xml_f="17117" txt_i="10594" txt_f="11169">-test was used for comparison between the two groups. Two-way ANOVA was used for comparison of the time course data of each group at the baseline and after 4 and 8 weeks of treatment. MRC scoring of the time course data of each group was performed by non-parametric two-way ANOVA corrected by post-testing. The relationship between the changes in each spirometric parameter and MRC score was tested by Spearman’s non-parametric correlation test. Data on the plasma concentration of theophylline were expressed as means ± SD and compared between the two groups by an unpaired </offsets><italic><offsets xml_i="17125" xml_f="17126" txt_i="11169" txt_f="11170">t</offsets></italic><offsets xml_i="17135" xml_f="17232" txt_i="11170" txt_f="11267">-test. Differences were considered statistically significant when the p value was less than 0.05.</offsets></p></sec></sec><sec sec-type="results"><title><offsets xml_i="17279" xml_f="17286" txt_i="11270" txt_f="11277">Results</offsets></title><sec><title><offsets xml_i="17306" xml_f="17314" txt_i="11278" txt_f="11286">Patients</offsets></title><p><offsets xml_i="17325" xml_f="17382" txt_i="11287" txt_f="11344">Demographic characteristics at the baseline are shown in </offsets><xref ref-type="table" rid="tbl1"><offsets xml_i="17416" xml_f="17423" txt_i="11344" txt_f="11351">Table 1</offsets></xref><offsets xml_i="17430" xml_f="18276" txt_i="11351" txt_f="12197">. There was no significance difference in demographic characteristics between the two groups at the end of the run-in period. Seventy-seven COPD patients were matched to the entry criteria and enrolled in the study; they received theophylline (200 mg twice daily) for 4-weeks as a run-in period. During the run-in period, 13 patients were withdrawn from the study: 7 patients had adverse events associated with the theophylline (anorexia, 4; emesis, 1; ischuria, 1; and stomatitis, 1); 4 patients refused for personal reasons to continue; 1 patient had accompanying asthma, and one had an exacerbation of COPD. During the 8-week treatment period, two and one patient dropped out from the combination and theophylline alone groups, respectively. Finally, data on 61 COPD patients (31 combination; 30 theophylline alone) were used in the analysis (</offsets><xref ref-type="fig" rid="fig2"><offsets xml_i="18308" xml_f="18316" txt_i="12197" txt_f="12205">Figure 2</offsets></xref><offsets xml_i="18323" xml_f="18411" txt_i="12205" txt_f="12293">). No subject in either group experienced disease exacerbation from baseline to 8 weeks.</offsets></p><table-wrap id="tbl1" position="float"><label><offsets xml_i="18461" xml_f="18468" txt_i="12294" txt_f="12301">Table 1</offsets></label><caption><p><offsets xml_i="18488" xml_f="18537" txt_i="12301" txt_f="12350">Characteristics of patients with COPD at baseline</offsets></p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1"></th><th align="left" valign="top" rowspan="1" colspan="1"><offsets xml_i="18699" xml_f="18723" txt_i="12351" txt_f="12375">Theophylline-alone group</offsets><break></break><offsets xml_i="18738" xml_f="18746" txt_i="12375" txt_f="12383">(n = 30)</offsets></th><th align="left" valign="top" rowspan="1" colspan="1"><offsets xml_i="18805" xml_f="18822" txt_i="12383" txt_f="12400">Combination group</offsets><break></break><offsets xml_i="18837" xml_f="18845" txt_i="12400" txt_f="12408">(n = 31)</offsets></th><th align="left" valign="top" rowspan="1" colspan="1"><offsets xml_i="18904" xml_f="18911" txt_i="12408" txt_f="12415">p value</offsets></th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="18981" xml_f="18993" txt_i="12415" txt_f="12427">Age, yr ± SD</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="19039" xml_f="19049" txt_i="12428" txt_f="12438">71.8 ± 8.1</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="19095" xml_f="19105" txt_i="12439" txt_f="12449">68.4 ± 9.1</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="19151" xml_f="19153" txt_i="12450" txt_f="12452">NS</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="19208" xml_f="19224" txt_i="12453" txt_f="12469">Sex, Female/Male</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="19270" xml_f="19274" txt_i="12470" txt_f="12474">2/28</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="19320" xml_f="19324" txt_i="12475" txt_f="12479">1/30</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="19370" xml_f="19372" txt_i="12480" txt_f="12482">NS</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="19427" xml_f="19456" txt_i="12483" txt_f="12512">Smoking history, Pack-yr ± SD</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="19502" xml_f="19513" txt_i="12513" txt_f="12524">66.7 ± 57.2</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="19559" xml_f="19570" txt_i="12525" txt_f="12536">57.5 ± 31.5</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="19616" xml_f="19618" txt_i="12537" txt_f="12539">NS</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="19673" xml_f="19700" txt_i="12540" txt_f="12567"> Current smoker, % patients</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="19746" xml_f="19755" txt_i="12568" txt_f="12577">13 (44.3)</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="19801" xml_f="19810" txt_i="12578" txt_f="12587">14 (45.2)</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="19856" xml_f="19858" txt_i="12588" txt_f="12590">NS</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="19913" xml_f="19934" txt_i="12591" txt_f="12612">Body mass index, kg/m</offsets><sup><offsets xml_i="19939" xml_f="19940" txt_i="12612" txt_f="12613">2</offsets></sup></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="19992" xml_f="20002" txt_i="12614" txt_f="12624">21.8 ± 3.6</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="20048" xml_f="20058" txt_i="12625" txt_f="12635">22.6 ± 3.0</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="20104" xml_f="20106" txt_i="12636" txt_f="12638">NS</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="20161" xml_f="20187" txt_i="12639" txt_f="12665">Severity of disease, n (%)</offsets></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="20380" xml_f="20395" txt_i="12669" txt_f="12684"> Mild (stage I)</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="20441" xml_f="20449" txt_i="12685" txt_f="12693">8 (26.7)</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="20495" xml_f="20503" txt_i="12694" txt_f="12702">4 (12.9)</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="20549" xml_f="20551" txt_i="12703" txt_f="12705">NS</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="20606" xml_f="20626" txt_i="12706" txt_f="12726"> Moderate (stage II)</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="20672" xml_f="20681" txt_i="12727" txt_f="12736">12 (40.0)</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="20727" xml_f="20736" txt_i="12737" txt_f="12746">13 (41.9)</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="20782" xml_f="20784" txt_i="12747" txt_f="12749">NS</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="20839" xml_f="20858" txt_i="12750" txt_f="12769"> Severe (stage III)</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="20904" xml_f="20913" txt_i="12770" txt_f="12779">10 (33.3)</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="20959" xml_f="20968" txt_i="12780" txt_f="12789">14 (45.2)</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="21014" xml_f="21016" txt_i="12790" txt_f="12792">NS</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="21071" xml_f="21100" txt_i="12793" txt_f="12822">MRC dyspnoea score, mean ± SD</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="21146" xml_f="21155" txt_i="12823" txt_f="12832">2.0 ± 1.1</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="21201" xml_f="21210" txt_i="12833" txt_f="12842">2.0 ± 1.1</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="21256" xml_f="21258" txt_i="12843" txt_f="12845">NS</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="21313" xml_f="21331" txt_i="12846" txt_f="12864">FVC (L), mean ± SD</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="21377" xml_f="21386" txt_i="12865" txt_f="12874">2.8 ± 0.9</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="21432" xml_f="21441" txt_i="12875" txt_f="12884">3.0 ± 0.8</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="21487" xml_f="21489" txt_i="12885" txt_f="12887">NS</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="21544" xml_f="21547" txt_i="12888" txt_f="12891">FEV</offsets><sub><offsets xml_i="21552" xml_f="21553" txt_i="12891" txt_f="12892">1</offsets></sub><offsets xml_i="21559" xml_f="21578" txt_i="12892" txt_f="12911">/FVC (%), mean ± SD</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="21624" xml_f="21635" txt_i="12912" txt_f="12923">49.8 ± 12.4</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="21681" xml_f="21692" txt_i="12924" txt_f="12935">47.1 ± 12.6</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="21738" xml_f="21740" txt_i="12936" txt_f="12938">NS</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="21795" xml_f="21817" txt_i="12939" txt_f="12961">Pre-medications, n (%)</offsets></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td><td align="left" rowspan="1" colspan="1"></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="22010" xml_f="22023" txt_i="12965" txt_f="12978"> Theophylline</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="22069" xml_f="22078" txt_i="12979" txt_f="12988">11 (36.7)</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="22124" xml_f="22132" txt_i="12989" txt_f="12997">6 (19.4)</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="22178" xml_f="22180" txt_i="12998" txt_f="13000">NS</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="22235" xml_f="22249" txt_i="13001" txt_f="13015"> Long-acting β</offsets><sub><offsets xml_i="22254" xml_f="22255" txt_i="13015" txt_f="13016">2</offsets></sub><offsets xml_i="22261" xml_f="22269" txt_i="13016" txt_f="13024">-agonist</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="22315" xml_f="22323" txt_i="13025" txt_f="13033">4 (13.3)</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="22369" xml_f="22376" txt_i="13034" txt_f="13041">1 (3.2)</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="22422" xml_f="22424" txt_i="13042" txt_f="13044">NS</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="22479" xml_f="22494" txt_i="13045" txt_f="13060"> Short-acting β</offsets><sub><offsets xml_i="22499" xml_f="22500" txt_i="13060" txt_f="13061">2</offsets></sub><offsets xml_i="22506" xml_f="22514" txt_i="13061" txt_f="13069">-agonist</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="22560" xml_f="22568" txt_i="13070" txt_f="13078">7 (23.3)</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="22614" xml_f="22621" txt_i="13079" txt_f="13086">2 (6.5)</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="22667" xml_f="22669" txt_i="13087" txt_f="13089">NS</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="22724" xml_f="22758" txt_i="13090" txt_f="13124"> Short-acting anticholinergic drug</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="22804" xml_f="22811" txt_i="13125" txt_f="13132">2 (6.7)</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="22857" xml_f="22864" txt_i="13133" txt_f="13140">2 (6.5)</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="22910" xml_f="22912" txt_i="13141" txt_f="13143">NS</offsets></td></tr><tr><td align="left" rowspan="1" colspan="1"><offsets xml_i="22967" xml_f="22990" txt_i="13144" txt_f="13167"> Inhaled corticosteroid</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="23036" xml_f="23044" txt_i="13168" txt_f="13176">5 (16.7)</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="23090" xml_f="23097" txt_i="13177" txt_f="13184">2 (6.5)</offsets></td><td align="left" rowspan="1" colspan="1"><offsets xml_i="23143" xml_f="23145" txt_i="13185" txt_f="13187">NS</offsets></td></tr></tbody></table><table-wrap-foot><fn id="tf1-1"><p><bold><offsets xml_i="23212" xml_f="23226" txt_i="13188" txt_f="13202">Abbreviations:</offsets></bold><offsets xml_i="23233" xml_f="23237" txt_i="13202" txt_f="13206"> FEV</offsets><sub><offsets xml_i="23242" xml_f="23243" txt_i="13206" txt_f="13207">1</offsets></sub><offsets xml_i="23249" xml_f="23363" txt_i="13207" txt_f="13321">, forced expiratory volume in one second; FVC, forced vital capacity; NS, not significant; SD, standard deviation.</offsets></p></fn></table-wrap-foot></table-wrap><fig id="fig2" position="float"><label><offsets xml_i="23442" xml_f="23450" txt_i="13322" txt_f="13330">Figure 2</offsets></label><caption><p><offsets xml_i="23470" xml_f="23484" txt_i="13330" txt_f="13344">Trial profile.</offsets></p></caption><graphic xlink:href="copd0301-137-02"></graphic></fig></sec><sec><title><offsets xml_i="23570" xml_f="23594" txt_i="13346" txt_f="13370">Pulmonary function tests</offsets></title><p><offsets xml_i="23605" xml_f="23620" txt_i="13371" txt_f="13386">The FVC and FEV</offsets><sub><offsets xml_i="23625" xml_f="23626" txt_i="13386" txt_f="13387">1</offsets></sub><offsets xml_i="23632" xml_f="23783" txt_i="13387" txt_f="13538"> values in the combination therapy group were significantly increased 4 and 8 weeks after the addition of tiotropium, when compared with the baseline (</offsets><xref ref-type="fig" rid="fig3"><offsets xml_i="23815" xml_f="23827" txt_i="13538" txt_f="13550">Figure 3a, b</offsets></xref><offsets xml_i="23834" xml_f="23856" txt_i="13550" txt_f="13572">). The increase in FEV</offsets><sub><offsets xml_i="23861" xml_f="23862" txt_i="13572" txt_f="13573">1</offsets></sub><offsets xml_i="23868" xml_f="24061" txt_i="13573" txt_f="13766"> from the baseline was 0.17 ± 0.03 L at 4 weeks and 0.21 ± 0.03 L at 8 weeks. In contrast, these effects were not observed in the theophylline-alone group. The percentage changes in FVC and FEV</offsets><sub><offsets xml_i="24066" xml_f="24067" txt_i="13766" txt_f="13767">1</offsets></sub><offsets xml_i="24073" xml_f="24216" txt_i="13767" txt_f="13910"> from the baseline were significantly increased at 4 and at 8 weeks in the combination therapy group, but not in the theophylline-alone group (</offsets><xref ref-type="fig" rid="fig3"><offsets xml_i="24248" xml_f="24260" txt_i="13910" txt_f="13922">Figure 3c, d</offsets></xref><offsets xml_i="24267" xml_f="24311" txt_i="13922" txt_f="13966">). In addition, the percentage change in FEV</offsets><sub><offsets xml_i="24316" xml_f="24317" txt_i="13966" txt_f="13967">1</offsets></sub><offsets xml_i="24323" xml_f="24425" txt_i="13967" txt_f="14069"> in the combination therapy group was significantly greater than that in the theophylline-alone group.</offsets></p><fig id="fig3" position="float"><label><offsets xml_i="24468" xml_f="24476" txt_i="14070" txt_f="14078">Figure 3</offsets></label><caption><p><offsets xml_i="24496" xml_f="24518" txt_i="14078" txt_f="14100">Changes in FVC and FEV</offsets><sub><offsets xml_i="24523" xml_f="24524" txt_i="14100" txt_f="14101">1</offsets></sub><offsets xml_i="24530" xml_f="24666" txt_i="14101" txt_f="14237"> in the theophylline alone (white squares) and the combination therapy group (black squares). In a and b, absolute values of FVC and FEV</offsets><sub><offsets xml_i="24671" xml_f="24672" txt_i="14237" txt_f="14238">1</offsets></sub><offsets xml_i="24678" xml_f="24735" txt_i="14238" txt_f="14295"> are shown. In c and d, percentage changes in FVC and FEV</offsets><sub><offsets xml_i="24740" xml_f="24741" txt_i="14295" txt_f="14296">1</offsets></sub><offsets xml_i="24747" xml_f="24776" txt_i="14296" txt_f="14325"> from the baseline are shown.</offsets></p><p><bold><offsets xml_i="24789" xml_f="24795" txt_i="14326" txt_f="14332">Notes:</offsets></bold><offsets xml_i="24802" xml_f="24879" txt_i="14332" txt_f="14400"> *p &lt; 0.05, **p &lt; 0.01, ***p &lt; 0.001 compared with baseline values. </offsets><sup><offsets xml_i="24884" xml_f="24885" txt_i="14400" txt_f="14401">†</offsets></sup><offsets xml_i="24891" xml_f="24922" txt_i="14401" txt_f="14429">p &lt; 0.05 between two groups.</offsets></p><p><bold><offsets xml_i="24935" xml_f="24949" txt_i="14430" txt_f="14444">Abbreviations:</offsets></bold><offsets xml_i="24956" xml_f="24988" txt_i="14444" txt_f="14476"> FVC, forced vital capacity; FEV</offsets><sub><offsets xml_i="24993" xml_f="24994" txt_i="14476" txt_f="14477">1</offsets></sub><offsets xml_i="25000" xml_f="25041" txt_i="14477" txt_f="14518">, forced expiratory volume in one second.</offsets></p></caption><graphic xlink:href="copd0301-137-03"></graphic></fig><p><xref ref-type="fig" rid="fig4"><offsets xml_i="25144" xml_f="25152" txt_i="14519" txt_f="14527">Figure 4</offsets></xref><offsets xml_i="25159" xml_f="25519" txt_i="14527" txt_f="14887"> shows the results from 42 subjects from both groups who did not receive theophylline at screening (25 combination; 17 theophylline-alone). Theophylline-alone group did not cause a significant improvement in pulmonary function and symptoms over the 12 weeks (4-week run-in plus 8-week therapeutic period). However, in the combination therapy group, FVC and FEV</offsets><sub><offsets xml_i="25524" xml_f="25525" txt_i="14887" txt_f="14888">1</offsets></sub><offsets xml_i="25531" xml_f="25594" txt_i="14888" txt_f="14951"> were significantly increased after the addition of tiotropium.</offsets></p><fig id="fig4" position="float"><label><offsets xml_i="25637" xml_f="25645" txt_i="14952" txt_f="14960">Figure 4</offsets></label><caption><p><offsets xml_i="25665" xml_f="25687" txt_i="14960" txt_f="14982">Changes in FVC and FEV</offsets><sub><offsets xml_i="25692" xml_f="25693" txt_i="14982" txt_f="14983">1</offsets></sub><offsets xml_i="25699" xml_f="25945" txt_i="14983" txt_f="15229"> in the theophylline-alone (white squares, n = 17) and the combination therapy group (black squares, n = 25), in patients who did not receive regular treatment with theophylline at the time of screening. In a and b, absolute values of FVC and FEV</offsets><sub><offsets xml_i="25950" xml_f="25951" txt_i="15229" txt_f="15230">1</offsets></sub><offsets xml_i="25957" xml_f="26014" txt_i="15230" txt_f="15287"> are shown. In c and d, percentage changes in FVC and FEV</offsets><sub><offsets xml_i="26019" xml_f="26020" txt_i="15287" txt_f="15288">1</offsets></sub><offsets xml_i="26026" xml_f="26055" txt_i="15288" txt_f="15317"> from the baseline are shown.</offsets></p><p><bold><offsets xml_i="26068" xml_f="26074" txt_i="15318" txt_f="15324">Notes:</offsets></bold><offsets xml_i="26081" xml_f="26162" txt_i="15324" txt_f="15396"> *p &lt; 0.05, **p &lt; 0.01, ***p &lt; 0.001 compared with the baseline values. </offsets><sup><offsets xml_i="26167" xml_f="26168" txt_i="15396" txt_f="15397">†</offsets></sup><offsets xml_i="26174" xml_f="26205" txt_i="15397" txt_f="15425">p &lt; 0.05 between two groups.</offsets></p><p><bold><offsets xml_i="26218" xml_f="26232" txt_i="15426" txt_f="15440">Abbreviations:</offsets></bold><offsets xml_i="26239" xml_f="26271" txt_i="15440" txt_f="15472"> FVC, forced vital capacity; FEV</offsets><sub><offsets xml_i="26276" xml_f="26277" txt_i="15472" txt_f="15473">1</offsets></sub><offsets xml_i="26283" xml_f="26324" txt_i="15473" txt_f="15514">, forced expiratory volume in one second.</offsets></p></caption><graphic xlink:href="copd0301-137-04"></graphic></fig><p><offsets xml_i="26395" xml_f="26489" txt_i="15515" txt_f="15609">After 8 weeks of treatment, VC, inspiratory capacity (IC), peak expiratory flow rate (PEFR), ⩒</offsets><sub><offsets xml_i="26494" xml_f="26496" txt_i="15609" txt_f="15611">50</offsets></sub><offsets xml_i="26502" xml_f="26509" txt_i="15611" txt_f="15618">, and ⩒</offsets><sub><offsets xml_i="26514" xml_f="26516" txt_i="15618" txt_f="15620">25</offsets></sub><offsets xml_i="26522" xml_f="26665" txt_i="15620" txt_f="15763"> were significantly higher than the baseline values in the combination group. These effects were not observed in the theophylline-alone group (</offsets><xref ref-type="fig" rid="fig5"><offsets xml_i="26697" xml_f="26705" txt_i="15763" txt_f="15771">Figure 5</offsets></xref><offsets xml_i="26712" xml_f="26714" txt_i="15771" txt_f="15773">).</offsets></p><fig id="fig5" position="float"><label><offsets xml_i="26757" xml_f="26765" txt_i="15774" txt_f="15782">Figure 5</offsets></label><caption><p><offsets xml_i="26785" xml_f="26811" txt_i="15782" txt_f="15808">Changes in VC, IC, PEFR, ⩒</offsets><sub><offsets xml_i="26816" xml_f="26818" txt_i="15808" txt_f="15810">50</offsets></sub><offsets xml_i="26824" xml_f="26830" txt_i="15810" txt_f="15816"> and ⩒</offsets><sub><offsets xml_i="26835" xml_f="26837" txt_i="15816" txt_f="15818">25</offsets></sub><offsets xml_i="26843" xml_f="26882" txt_i="15818" txt_f="15857"> at 8 weeks. Changes in VC, IC, PEFR, ⩒</offsets><sub><offsets xml_i="26887" xml_f="26889" txt_i="15857" txt_f="15859">50</offsets></sub><offsets xml_i="26895" xml_f="26902" txt_i="15859" txt_f="15866">, and ⩒</offsets><sub><offsets xml_i="26907" xml_f="26909" txt_i="15866" txt_f="15868">25</offsets></sub><offsets xml_i="26915" xml_f="27036" txt_i="15868" txt_f="15989"> at 8 weeks were analyzed in theophylline-alone (white bars, n = 26) and combination therapy (solid bars, n = 30) groups.</offsets></p><p><bold><offsets xml_i="27049" xml_f="27055" txt_i="15990" txt_f="15996">Notes:</offsets></bold><offsets xml_i="27062" xml_f="27108" txt_i="15996" txt_f="16039"> *p &lt; 0.05 compared with screening values. </offsets><sup><offsets xml_i="27113" xml_f="27114" txt_i="16039" txt_f="16040">†</offsets></sup><offsets xml_i="27120" xml_f="27151" txt_i="16040" txt_f="16068">p &lt; 0.05 between two groups.</offsets></p><p><bold><offsets xml_i="27164" xml_f="27178" txt_i="16069" txt_f="16083">Abbreviations:</offsets></bold><offsets xml_i="27185" xml_f="27264" txt_i="16083" txt_f="16162"> IC, inspiratory capacity; PEFR, peak expiratory flow rate; VC, vital capacity.</offsets></p></caption><graphic xlink:href="copd0301-137-05"></graphic></fig></sec><sec><title><offsets xml_i="27350" xml_f="27359" txt_i="16164" txt_f="16173">MRC score</offsets></title><p><offsets xml_i="27370" xml_f="28124" txt_i="16174" txt_f="16922">MRC score was analyzed in 59 of 61 patients (two patients withdrew from the study at the stage of MRC scoring). MRC scores in the theophylline-alone group (n = 29) at screening, baseline, and 4 and 8 weeks after treatment were 2.00 ± 1.10, 1.75 ± 1.14, 2.04 ± 0.94, and 2.04 ± 1.21, respectively. The respective MRC scores in the combination group (n = 30) were 2.03 ± 1.10, 2.03 ± 1.19, 1.57 ± 1.14, and 1.57 ± 1.14. When compared with the baseline values, the mean MRC score in the combination group was significantly decreased by 0.46 (p &lt; 0.01) and 0.46 (p &lt; 0.05) at 4 and 8 weeks after treatment, respectively. The improvement was small but clinically meaningful, because the changes in MRC score were greater than those in a previous study (</offsets><xref ref-type="bibr" rid="b1"><offsets xml_i="28155" xml_f="28174" txt_i="16922" txt_f="16941">Akamatsu et al 2007</offsets></xref><offsets xml_i="28181" xml_f="28382" txt_i="16941" txt_f="17142">). In contrast, there was no significant change in the theophylline-alone group when compared with baseline. There was no significant difference in MRC score between the two groups at each time point (</offsets><xref ref-type="fig" rid="fig6"><offsets xml_i="28414" xml_f="28423" txt_i="17142" txt_f="17151">Figure 6a</offsets></xref><offsets xml_i="28430" xml_f="28432" txt_i="17151" txt_f="17153">).</offsets></p><fig id="fig6" position="float"><label><offsets xml_i="28475" xml_f="28483" txt_i="17154" txt_f="17162">Figure 6</offsets></label><caption><p><offsets xml_i="28503" xml_f="28598" txt_i="17162" txt_f="17257">British Medical Research Council (MRC) scores 4 and 8 weeks after the addition of tiotropium. (</offsets><bold><offsets xml_i="28604" xml_f="28605" txt_i="17257" txt_f="17258">a</offsets></bold><offsets xml_i="28612" xml_f="28783" txt_i="17258" txt_f="17429">) MRC scores 4 and 8 weeks after the addition of tiotropium were analyzed in theophylline-alone (white bars, n = 29) and combination therapy (solid bars, n = 30) groups. (</offsets><bold><offsets xml_i="28789" xml_f="28790" txt_i="17429" txt_f="17430">b</offsets></bold><offsets xml_i="28797" xml_f="29033" txt_i="17430" txt_f="17666">) MRC scores 4 and 8 weeks after the addition of tiotropium were analyzed in 42 patients who were not receiving theophylline at the time of screening: theophylline-alone (white bars, n = 17) and combination therapy (solid bars, n = 25).</offsets></p><p><bold><offsets xml_i="29046" xml_f="29052" txt_i="17667" txt_f="17673">Notes:</offsets></bold><offsets xml_i="29059" xml_f="29116" txt_i="17673" txt_f="17724"> *p &lt; 0.05, p &lt; 0.01 compared with baseline values.</offsets></p></caption><graphic xlink:href="copd0301-137-06"></graphic></fig><p><offsets xml_i="29187" xml_f="29870" txt_i="17725" txt_f="18402">Next, we performed a sub-analysis of 42 of these 59 patients who were not receiving theophylline at screening to determine the therapeutic effects of theophylline itself. MRC scores at screening, baseline, and 4 and 8 weeks after treatment in the theophylline-alone group (n = 17) were 1.85 ± 1.14, 1.74 ± 1.15, 1.95 ± 1.03, and 1.88 ± 1.32, respectively. The respective MRC scores in the combination group (n = 25) were 2.08 ± 1.15, 2.12 ± 1.24, 1.60 ± 1.15, and 1.58 ± 1.21. When compared with the baseline values, the mean MRC score in the combination group was significantly decreased by 0.52 (p &lt; 0.01) and 0.54 (p &lt; 0.05) at 4 and 8 weeks, respectively, after treatment (</offsets><xref ref-type="fig" rid="fig6"><offsets xml_i="29902" xml_f="29911" txt_i="18402" txt_f="18411">Figure 6b</offsets></xref><offsets xml_i="29918" xml_f="29920" txt_i="18411" txt_f="18413">).</offsets></p></sec><sec><title><offsets xml_i="29942" xml_f="29962" txt_i="18415" txt_f="18435">Physical examination</offsets></title><p><offsets xml_i="29973" xml_f="30282" txt_i="18436" txt_f="18745">No significant difference was observed between the two groups in terms of respiratory rates, blood pressure, heart rates, body temperature, and oxygen saturation of arterial blood by pulse oximeter at the screening visit, at the baseline, and after 4 and 8 weeks of treatment with tiotropium (data not shown).</offsets></p><p><offsets xml_i="30289" xml_f="30705" txt_i="18746" txt_f="19162">Serum theophylline concentrations at the baseline and after 4 and 8 weeks of treatment were 8.6 ± 5.0, 8.9 ± 5.5, and 8.5 ± 4.7 μg/mL in the theophylline-alone group, and 9.5 ± 5.7, 9.4 ± 3.6, and 9.1 ± 4.9 μg/mL in the combination therapy group, respectively. There were no significant differences between the two groups at any time. Serum theophylline levels greater than 20 μg/mL were not observed in any patient.</offsets></p></sec><sec><title><offsets xml_i="30727" xml_f="30741" txt_i="19164" txt_f="19178">Adverse events</offsets></title><p><offsets xml_i="30752" xml_f="31471" txt_i="19179" txt_f="19898">During the run-in period, 7 patients dropped out because of theophylline-related adverse events, as described above. We observed 9 adverse events during the treatment period. Two and 7 adverse events were observed in the theophylline-alone group and the combination therapy group, respectively. In the theophylline-alone group, these events were anorexia (n = 1) and hematuria (n = 1). In the combination therapy group, they were dry mouth (n = 2), pharyngolaryngeal paresthesia (n = 3), fatigue (n = 1), and bitter taste (n = 1). One of the patients with emesis dropped out of the theophylline-alone group, and one with dry mouth and one with pharyngolaryngeal paresthesia dropped out of the combination therapy group.</offsets></p></sec></sec><sec sec-type="discussion"><title><offsets xml_i="31521" xml_f="31531" txt_i="19901" txt_f="19911">Discussion</offsets></title><p><offsets xml_i="31542" xml_f="31950" txt_i="19912" txt_f="20320">To our knowledge, this is the first study to show the efficacy and safety of tiotropium add-on therapy in COPD patients treated with theophylline. We demonstrated that add-on therapy with tiotropium significantly improved the MRC dyspnea score and pulmonary function in COPD patients already being treated with theophylline. According to the GOLD guidelines, combination therapy with different kinds of bronc</offsets><xref ref-type="bibr" rid="b17"><offsets xml_i="31982" xml_f="31991" txt_i="20320" txt_f="20329">Gold 2006</offsets></xref><offsets xml_i="31998" xml_f="32000" txt_i="20329" txt_f="20331">).</offsets></p><p><offsets xml_i="32007" xml_f="32142" txt_i="20332" txt_f="20467">Previous studies have reported that treatment with relatively low dose of theophylline has anti-inflammatory effects in COPD patients (</offsets><xref ref-type="bibr" rid="b12"><offsets xml_i="32174" xml_f="32192" txt_i="20467" txt_f="20485">Culpitt et al 2002</offsets></xref><offsets xml_i="32199" xml_f="32201" txt_i="20485" txt_f="20487">; </offsets><xref ref-type="bibr" rid="b28"><offsets xml_i="32233" xml_f="32253" txt_i="20487" txt_f="20507">Kobayashi et al 2004</offsets></xref><offsets xml_i="32260" xml_f="32262" txt_i="20507" txt_f="20509">; </offsets><xref ref-type="bibr" rid="b20"><offsets xml_i="32294" xml_f="32311" txt_i="20509" txt_f="20526">Hirano et al 2006</offsets></xref><offsets xml_i="32318" xml_f="32878" txt_i="20526" txt_f="21086">). These patients were treated with theophylline at 400 mg/day, and/or plasma levels of theophylline were approximately 5 to 10 mg/L. These concentrations of theophylline had anti-inflammatory effects. However, these studies did not determine whether theophylline had clinical benefits on pulmonary function or physical condition in COPD patients. The Japanese Respiratory Society’s guidelines for the diagnosis and treatment of COPD suggested that low dose of theophylline may be effective for COPD patients, as high doses of theophylline have toxic effects (</offsets><xref ref-type="bibr" rid="b18"><offsets xml_i="32910" xml_f="32965" txt_i="21086" txt_f="21141">Guidelines for the Diagnosis and Treatment of COPD 2006</offsets></xref><offsets xml_i="32972" xml_f="33221" txt_i="21141" txt_f="21390">). On the basis of these studies, we treated COPD patients with 400 mg theophylline (200 mg twice daily). Plasma levels of theophylline were approximately 8 to 10 mg/L in these patients, and theophylline alone did not improve pulmonary function (FEV</offsets><sub><offsets xml_i="33226" xml_f="33227" txt_i="21390" txt_f="21391">1</offsets></sub><offsets xml_i="33233" xml_f="33420" txt_i="21391" txt_f="21578">) or MRC scores in 30 COPD patients analyzed. Moreover, in 17 patients who were not receiving theophylline at screening, treatment with theophylline alone did not improve MRC score or FEV</offsets><sub><offsets xml_i="33425" xml_f="33426" txt_i="21578" txt_f="21579">1</offsets></sub><offsets xml_i="33432" xml_f="33556" txt_i="21579" txt_f="21703">. The possibility remains that this concentration of theophylline in the plasma may not exert sufficient bronchodilatation (</offsets><xref ref-type="bibr" rid="b29"><offsets xml_i="33588" xml_f="33612" txt_i="21703" txt_f="21727">Mitenko and Ogilvie 1973</offsets></xref><offsets xml_i="33619" xml_f="33712" txt_i="21727" txt_f="21820">). Here we evaluated whether the combination of theophylline and tiotropium could improve FEV</offsets><sub><offsets xml_i="33717" xml_f="33718" txt_i="21820" txt_f="21821">1</offsets></sub><offsets xml_i="33724" xml_f="33827" txt_i="21821" txt_f="21924"> and MRC scores in COPD patients, and we compared our results with those of previous studies in Japan (</offsets><xref ref-type="bibr" rid="b21"><offsets xml_i="33859" xml_f="33876" txt_i="21924" txt_f="21941">Hirata et al 2003</offsets></xref><offsets xml_i="33883" xml_f="33885" txt_i="21941" txt_f="21943">; </offsets><xref ref-type="bibr" rid="b22"><offsets xml_i="33917" xml_f="33936" txt_i="21943" txt_f="21962">Ichinose et al 2003</offsets></xref><offsets xml_i="33943" xml_f="33945" txt_i="21962" txt_f="21964">).</offsets></p><p><offsets xml_i="33952" xml_f="34213" txt_i="21965" txt_f="22226">A study that compared the effects of the short-acting anticholinergic ipratropium and theophylline reported that improvement of pulmonary function and exercise endurance was significantly greater in the combination therapy group than in each monotherapy group (</offsets><xref ref-type="bibr" rid="b37"><offsets xml_i="34245" xml_f="34263" txt_i="22226" txt_f="22244">Tsukino et al 1998</offsets></xref><offsets xml_i="34270" xml_f="34439" txt_i="22244" txt_f="22413">). In addition, a combination of the short-acting anti-cholinergic oxitropium and theophylline improved QOL to a significantly greater extent than did each monotherapy (</offsets><xref ref-type="bibr" rid="b6"><offsets xml_i="34470" xml_f="34487" txt_i="22413" txt_f="22430">Bellia et al 2002</offsets></xref><offsets xml_i="34494" xml_f="34553" txt_i="22430" txt_f="22489">). Furthermore, combination treatment with a short-acting β</offsets><sub><offsets xml_i="34558" xml_f="34559" txt_i="22489" txt_f="22490">2</offsets></sub><offsets xml_i="34565" xml_f="34682" txt_i="22490" txt_f="22607">-agonist, a short-acting anticholinergic agent, and oral theophylline led to significantly greater improvement in FEV</offsets><sub><offsets xml_i="34687" xml_f="34688" txt_i="22607" txt_f="22608">1</offsets></sub><offsets xml_i="34694" xml_f="34773" txt_i="22608" txt_f="22687"> compared with the results of monotherapy, without any severe adverse effects (</offsets><xref ref-type="bibr" rid="b26"><offsets xml_i="34805" xml_f="34822" txt_i="22687" txt_f="22704">Karpel et al 1994</offsets></xref><offsets xml_i="34829" xml_f="34831" txt_i="22704" txt_f="22706">).</offsets></p><p><offsets xml_i="34838" xml_f="34948" txt_i="22707" txt_f="22817">Long-acting bronchodilators have recently become standard medicines in the pharmacological treatment of COPD (</offsets><xref ref-type="bibr" rid="b17"><offsets xml_i="34980" xml_f="34989" txt_i="22817" txt_f="22826">Gold 2006</offsets></xref><offsets xml_i="34996" xml_f="35299" txt_i="22826" txt_f="23129">). Therefore, the establishment of combination therapy for COPD with long-acting bronchodilators is an expected trend. Combination of the LABA salmeterol with theophylline leads to significantly better pulmonary functions, greater improvement in symptoms, improved reduction in the use of short-acting β</offsets><sub><offsets xml_i="35304" xml_f="35305" txt_i="23129" txt_f="23130">2</offsets></sub><offsets xml_i="35311" xml_f="35406" txt_i="23130" txt_f="23225">-agonists, and decrease in exacerbation frequency compared with the use of theophylline alone (</offsets><xref ref-type="bibr" rid="b41"><offsets xml_i="35438" xml_f="35458" txt_i="23225" txt_f="23245">Zuwallack et al 2001</offsets></xref><offsets xml_i="35465" xml_f="35685" txt_i="23245" txt_f="23465">). In both stable COPD patients and those with exacerbations, combination therapy with the inhaled LABA formoterol and the inhaled long-acting anticholinergic tiotropium improves pulmonary function indicators such as FEV</offsets><sub><offsets xml_i="35690" xml_f="35691" txt_i="23465" txt_f="23466">1</offsets></sub><offsets xml_i="35697" xml_f="35781" txt_i="23466" txt_f="23550">, IC, and FVC to a significantly greater extent than is seen with each agent alone (</offsets><xref ref-type="bibr" rid="b13"><offsets xml_i="35813" xml_f="35832" txt_i="23550" txt_f="23569">Di Marco et al 2006</offsets></xref><offsets xml_i="35839" xml_f="35841" txt_i="23569" txt_f="23571">; </offsets><xref ref-type="bibr" rid="b39"><offsets xml_i="35873" xml_f="35893" txt_i="23571" txt_f="23591">Van Noord et al 2006</offsets></xref><offsets xml_i="35900" xml_f="36035" txt_i="23591" txt_f="23726">). A previous study also showed additional clinical improvement when COPD patients were treated with theophylline added to salmeterol (</offsets><xref ref-type="bibr" rid="b41"><offsets xml_i="36067" xml_f="36087" txt_i="23726" txt_f="23746">Zuwallack et al 2001</offsets></xref><offsets xml_i="36094" xml_f="36248" txt_i="23746" txt_f="23900">). However, evidence of the effects of combination therapy with long-acting bronchodilators, especially anticholinergics and theophylline, is still scant.</offsets></p><p><offsets xml_i="36255" xml_f="36349" txt_i="23901" txt_f="23995">One recent study reported the effect of combination therapy with tiotropium and theophylline (</offsets><xref ref-type="bibr" rid="b9"><offsets xml_i="36380" xml_f="36413" txt_i="23995" txt_f="24028">Cazzola and Gabriella Matera 2007</offsets></xref><offsets xml_i="36420" xml_f="37004" txt_i="24028" txt_f="24612">). They investigated the additive effect of theophylline in patients with stable COPD who were receiving both tiotropium and formoterol. Although their findings question the importance of adding theophylline in stable COPD patients already being treated with two long-acting bronchodilators, they also indicate that some patients may benefit from theophylline because of symptomatic improvement. We chose to investigate the effects of adding tiotropium in patients already treated with theophylline because theophylline is widely used for COPD treatment, both in Japan and worldwide (</offsets><xref ref-type="bibr" rid="b23"><offsets xml_i="37036" xml_f="37055" txt_i="24612" txt_f="24631">Ichinose et al 2006</offsets></xref><offsets xml_i="37062" xml_f="37064" txt_i="24631" txt_f="24633">).</offsets></p><p><offsets xml_i="37071" xml_f="37426" txt_i="24634" txt_f="24989">Dyspnea upon exercise is one of the most important symptoms in patients with COPD. We used the MRC dyspnea score to assess symptoms: the MRC questionnaire can easily classify symptom severity. We demonstrated that the mean MRC dyspnea score in patients with combination therapy improved significantly after both 4 and 8 weeks of tiotropium add-on therapy.</offsets></p><p><offsets xml_i="37433" xml_f="37548" txt_i="24990" txt_f="25105">The beneficial effect of combination therapy might be attributable to the different mechanisms of bronchodilation (</offsets><xref ref-type="bibr" rid="b36"><offsets xml_i="37580" xml_f="37594" txt_i="25105" txt_f="25119">Thirstrup 2000</offsets></xref><offsets xml_i="37601" xml_f="37807" txt_i="25119" txt_f="25325">). Theophylline had been reported to have extrapulmonary effects, such as increased diaphragmatic contractility and reversed diaphragm fatigue, although the validity of these effects remains controversial (</offsets><xref ref-type="bibr" rid="b3"><offsets xml_i="37838" xml_f="37855" txt_i="25325" txt_f="25342">Aubier et al 1981</offsets></xref><offsets xml_i="37862" xml_f="37976" txt_i="25342" txt_f="25456">). There is also increasing evidence that low-dose theophylline has anti-inflammatory effects in asthma and COPD (</offsets><xref ref-type="bibr" rid="b12"><offsets xml_i="38008" xml_f="38026" txt_i="25456" txt_f="25474">Culpitt et al 2002</offsets></xref><offsets xml_i="38033" xml_f="38035" txt_i="25474" txt_f="25476">; </offsets><xref ref-type="bibr" rid="b11"><offsets xml_i="38067" xml_f="38083" txt_i="25476" txt_f="25492">Cosio et al 2004</offsets></xref><offsets xml_i="38090" xml_f="38092" txt_i="25492" txt_f="25494">; </offsets><xref ref-type="bibr" rid="b5"><offsets xml_i="38123" xml_f="38140" txt_i="25494" txt_f="25511">Barnes et al 2005</offsets></xref><offsets xml_i="38147" xml_f="38149" txt_i="25511" txt_f="25513">).</offsets></p><p><offsets xml_i="38156" xml_f="38310" txt_i="25514" txt_f="25668">The effects of treatment with tiotropium alone on pulmonary function, when compared with placebo, include improvements in peak expiratory flow volume, FEV</offsets><sub><offsets xml_i="38315" xml_f="38316" txt_i="25668" txt_f="25669">1</offsets></sub><offsets xml_i="38322" xml_f="38341" txt_i="25669" txt_f="25688">, FVC, VC, and IC (</offsets><xref ref-type="bibr" rid="b8"><offsets xml_i="38372" xml_f="38391" txt_i="25688" txt_f="25707">Casaburi et al 2002</offsets></xref><offsets xml_i="38398" xml_f="38400" txt_i="25707" txt_f="25709">; </offsets><xref ref-type="bibr" rid="b40"><offsets xml_i="38432" xml_f="38450" txt_i="25709" txt_f="25727">Vincken et al 2002</offsets></xref><offsets xml_i="38457" xml_f="38459" txt_i="25727" txt_f="25729">; </offsets><xref ref-type="bibr" rid="b7"><offsets xml_i="38490" xml_f="38509" txt_i="25729" txt_f="25748">Brusasco et al 2003</offsets></xref><offsets xml_i="38516" xml_f="38518" txt_i="25748" txt_f="25750">; </offsets><xref ref-type="bibr" rid="b10"><offsets xml_i="38550" xml_f="38566" txt_i="25750" txt_f="25766">Celli et al 2003</offsets></xref><offsets xml_i="38573" xml_f="38575" txt_i="25766" txt_f="25768">; </offsets><xref ref-type="bibr" rid="b33"><offsets xml_i="38607" xml_f="38627" txt_i="25768" txt_f="25788">O’Donnell et al 2004</offsets></xref><offsets xml_i="38634" xml_f="38636" txt_i="25788" txt_f="25790">; </offsets><xref ref-type="bibr" rid="b39"><offsets xml_i="38668" xml_f="38688" txt_i="25790" txt_f="25810">Van Noord et al 2006</offsets></xref><offsets xml_i="38695" xml_f="38814" txt_i="25810" txt_f="25929">). Our findings confirmed these previous observations. In the study of Japanese COPD patients, the increase in peak FEV</offsets><sub><offsets xml_i="38819" xml_f="38820" txt_i="25929" txt_f="25930">1</offsets></sub><offsets xml_i="38826" xml_f="38896" txt_i="25930" txt_f="26000"> with tiotropium alone was 0.20 ± 0.02 L after 6 months of treatment (</offsets><xref ref-type="bibr" rid="b21"><offsets xml_i="38928" xml_f="38945" txt_i="26000" txt_f="26017">Hirata et al 2003</offsets></xref><offsets xml_i="38952" xml_f="38954" txt_i="26017" txt_f="26019">; </offsets><xref ref-type="bibr" rid="b22"><offsets xml_i="38986" xml_f="39005" txt_i="26019" txt_f="26038">Ichinose et al 2003</offsets></xref><offsets xml_i="39012" xml_f="39093" txt_i="26038" txt_f="26119">). In our patients, addition of tiotropium to theophylline increased the mean FEV</offsets><sub><offsets xml_i="39098" xml_f="39099" txt_i="26119" txt_f="26120">1</offsets></sub><offsets xml_i="39105" xml_f="39198" txt_i="26120" txt_f="26213"> by 0.17 ± 0.03 L and 0.21 ± 0.03 L after 4 and 8 weeks, respectively. These increases in FEV</offsets><sub><offsets xml_i="39203" xml_f="39204" txt_i="26213" txt_f="26214">1</offsets></sub><offsets xml_i="39210" xml_f="39258" txt_i="26214" txt_f="26262"> were similar to those in other investigations (</offsets><xref ref-type="bibr" rid="b21"><offsets xml_i="39290" xml_f="39307" txt_i="26262" txt_f="26279">Hirata et al 2003</offsets></xref><offsets xml_i="39314" xml_f="39316" txt_i="26279" txt_f="26281">; </offsets><xref ref-type="bibr" rid="b22"><offsets xml_i="39348" xml_f="39367" txt_i="26281" txt_f="26300">Ichinose et al 2003</offsets></xref><offsets xml_i="39374" xml_f="39788" txt_i="26300" txt_f="26714">). Our present study did not include a group of patients treated with tiotropium alone, so we were unable to assess whether there was any benefit of adding theophylline to patients treated with tiotropium. The above-mentioned recent study in which the add-on effect of theophylline was investigated in patients already being treated with tiotropium and formoterol reported a limited effect of theophylline add-on (</offsets><xref ref-type="bibr" rid="b9"><offsets xml_i="39819" xml_f="39852" txt_i="26714" txt_f="26747">Cazzola and Gabriella Matera 2007</offsets></xref><offsets xml_i="39859" xml_f="40004" txt_i="26747" txt_f="26892">). Evaluation of all of these results together indicates that tiotropium is a useful addition in COPD patients already treated with theophylline.</offsets></p></sec></body><back><ack><p>We especially thank Dr Gail M Gauvreau of the Asthma Research Group, McMaster University, Canada, for critical reading of this manuscript. This work was supported by Nippon Boehringer Ingelheim Co, Ltd (Tokyo, Japan) and by a Grant-in-Aid for Scientific Research (B) (no. 18390244) and Grants-in-Aid for Scientific Research (B) (no. 17390244) and Exploratory Research (no. 18659244) from the Ministry of Education, Science, Sports, and Culture of Japan.</p></ack><ref-list><title>References</title><ref id="b1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Akamatsu</surname><given-names>K</given-names></name><name><surname>Yamagata</surname><given-names>T</given-names></name><name><surname>Takahashi</surname><given-names>T</given-names></name><etal></etal></person-group><article-title>Improvement of pulmonary function and dyspnea by tiotropium in COPD patients using a transdermal beta(2)-agonist</article-title><source>Pulm Pharmacol Ther</source><year>2007</year><volume>20</volume><fpage>701</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">17049894</pub-id></citation></ref><ref id="b2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Anzueto</surname><given-names>A</given-names></name><name><surname>Tashkin</surname><given-names>D</given-names></name><name><surname>Menjoge</surname><given-names>S</given-names></name><etal></etal></person-group><article-title>One-year analysis of longitudinal changes in spirometry in patients with COPD receiving tiotropium</article-title><source>Pulm Pharmacol Ther</source><year>2005</year><volume>18</volume><fpage>75</fpage><lpage>81</lpage><pub-id pub-id-type="pmid">15649848</pub-id></citation></ref><ref id="b3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Aubier</surname><given-names>M</given-names></name><name><surname>De Troyer</surname><given-names>A</given-names></name><name><surname>Sampson</surname><given-names>M</given-names></name><etal></etal></person-group><article-title>Aminophylline improves diaphragmatic contractility</article-title><source>N Engl J Med</source><year>1981</year><volume>305</volume><fpage>249</fpage><lpage>52</lpage><pub-id pub-id-type="pmid">7242614</pub-id></citation></ref><ref id="b4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Barnes</surname><given-names>PJ</given-names></name></person-group><article-title>Current therapies for asthma. Promise and limitations</article-title><source>Chest</source><year>1997</year><volume>111</volume><fpage>17S</fpage><lpage>26S</lpage><pub-id pub-id-type="pmid">9042023</pub-id></citation></ref><ref id="b5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Barnes</surname><given-names>PJ</given-names></name><name><surname>Adcock</surname><given-names>IM</given-names></name><name><surname>Ito</surname><given-names>K</given-names></name></person-group><article-title>Histone acetylation and deacetylation: importance in inflammatory lung diseases</article-title><source>Eur Respir J</source><year>2005</year><volume>25</volume><fpage>552</fpage><lpage>63</lpage><pub-id pub-id-type="pmid">15738302</pub-id></citation></ref><ref id="b6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bellia</surname><given-names>V</given-names></name><name><surname>Foresi</surname><given-names>A</given-names></name><name><surname>Bianco</surname><given-names>S</given-names></name><etal></etal></person-group><article-title>Efficacy and safety of oxitropium bromide, theophylline and their combination in COPD patients: a double-blind, randomized, multicentre study (BREATH Trial)</article-title><source>Respir Med</source><year>2002</year><volume>96</volume><fpage>881</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">12418585</pub-id></citation></ref><ref id="b7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Brusasco</surname><given-names>V</given-names></name><name><surname>Hodder</surname><given-names>R</given-names></name><name><surname>Miravitlles</surname><given-names>M</given-names></name><etal></etal></person-group><article-title>Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD</article-title><source>Thorax</source><year>2003</year><volume>58</volume><fpage>399</fpage><lpage>404</lpage><pub-id pub-id-type="pmid">12728159</pub-id></citation></ref><ref id="b8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Casaburi</surname><given-names>R</given-names></name><name><surname>Mahler</surname><given-names>DA</given-names></name><name><surname>Jones</surname><given-names>PW</given-names></name><etal></etal></person-group><article-title>A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease</article-title><source>Eur Respir J</source><year>2002</year><volume>19</volume><fpage>217</fpage><lpage>24</lpage><pub-id pub-id-type="pmid">11866001</pub-id></citation></ref><ref id="b9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cazzola</surname><given-names>M</given-names></name><name><surname>Gabriella Matera</surname><given-names>M</given-names></name></person-group><article-title>The additive effect of theophylline on a combination of formoterol and tiotropium in stable COPD: a pilot study</article-title><source>Respir Med</source><year>2007</year><volume>101</volume><fpage>957</fpage><lpage>62</lpage><pub-id pub-id-type="pmid">17056241</pub-id></citation></ref><ref id="b10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Celli</surname><given-names>B</given-names></name><name><surname>ZuWallack</surname><given-names>R</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><etal></etal></person-group><article-title>Improvement in resting inspiratory capacity and hyperinflation with tiotropium in COPD patients with increased static lung volumes</article-title><source>Chest</source><year>2003</year><volume>124</volume><fpage>1743</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">14605043</pub-id></citation></ref><ref id="b11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cosio</surname><given-names>BG</given-names></name><name><surname>Tsaprouni</surname><given-names>L</given-names></name><name><surname>Ito</surname><given-names>K</given-names></name><etal></etal></person-group><article-title>Theophylline restores histone deacetylase activity and steroid responses in COPD macrophages</article-title><source>J Exp Med</source><year>2004</year><volume>200</volume><fpage>689</fpage><lpage>95</lpage><pub-id pub-id-type="pmid">15337792</pub-id></citation></ref><ref id="b12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Culpitt</surname><given-names>SV</given-names></name><name><surname>de Matos</surname><given-names>C</given-names></name><name><surname>Russell</surname><given-names>RE</given-names></name><etal></etal></person-group><article-title>Effect of theophylline on induced sputum inflammatory indices and neutrophil chemotaxis in chronic obstructive pulmonary disease</article-title><source>Am J Respir Crit Care Med</source><year>2002</year><volume>165</volume><fpage>1371</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">12016098</pub-id></citation></ref><ref id="b13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Di Marco</surname><given-names>F</given-names></name><name><surname>Verga</surname><given-names>M</given-names></name><name><surname>Santus</surname><given-names>P</given-names></name><etal></etal></person-group><article-title>Effect of formoterol, tiotropium, and their combination in patients with acute exacerbation of chronic obstructive pulmonary disease: a pilot study</article-title><source>Respir Med</source><year>2006</year><volume>100</volume><fpage>1925</fpage><lpage>32</lpage><pub-id pub-id-type="pmid">16626956</pub-id></citation></ref><ref id="b14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Disse</surname><given-names>B</given-names></name><name><surname>Speck</surname><given-names>GA</given-names></name><name><surname>Rominger</surname><given-names>KL</given-names></name><etal></etal></person-group><article-title>Tiotropium (Spiriva): mechanistical considerations and clinical profile in obstructive lung disease</article-title><source>Life Sci</source><year>1999</year><volume>64</volume><fpage>457</fpage><lpage>64</lpage><pub-id pub-id-type="pmid">10069510</pub-id></citation></ref><ref id="b15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Donohue</surname><given-names>JF</given-names></name></person-group><article-title>Combination therapy for chronic obstructive pulmonary disease: clinical aspects</article-title><source>Proc Am Thorac Soc</source><year>2005</year><volume>2</volume><fpage>272</fpage><lpage>81</lpage><comment>discussion: 90–1</comment><pub-id pub-id-type="pmid">16267348</pub-id></citation></ref><ref id="b16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dusser</surname><given-names>D</given-names></name><name><surname>Bravo</surname><given-names>ML</given-names></name><name><surname>Iacono</surname><given-names>P</given-names></name></person-group><article-title>The effect of tiotropium on exacerbations and airflow in patients with COPD</article-title><source>Eur Respir J</source><year>2006</year><volume>27</volume><fpage>547</fpage><lpage>55</lpage><pub-id pub-id-type="pmid">16507855</pub-id></citation></ref><ref id="b17"><citation citation-type="book"><collab>[GOLD] Global Initiative for Chronic Obstructive Lung Disease</collab><article-title>Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease</article-title><source>NHLBI/WHO workshop report</source><year>2006</year><publisher-loc>Bethesda</publisher-loc><publisher-name>National Heart, Lung and Blood Institute</publisher-name><comment>online Accessed 11 November 2006. URL: <ext-link ext-link-type="uri" xlink:href="http://www.goldcopd.com"></ext-link></comment></citation></ref><ref id="b18"><citation citation-type="web"><collab>Guidelines for the diagnosis and treatment of COPD</collab><article-title>Guidelines for the diagnosis and treatment of COPD</article-title><source>Committee for the second edition of the COPD guidelines of the Japanese Respiratory Society</source><year>2006</year><edition>2</edition><comment>online URL: <ext-link ext-link-type="uri" xlink:href="http://www.jrs.or.jp/quicklink/glsm/guideline/nopass_pdf/copd_summary_e.pdf"></ext-link></comment></citation></ref><ref id="b19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Guyatt</surname><given-names>Gh</given-names></name><name><surname>Townsend</surname><given-names>M</given-names></name><name><surname>Pugsley</surname><given-names>So</given-names></name><etal></etal></person-group><article-title>Bronchodilators in chronic air-flow limitation. Effects on airway function, exercise capacity, and quality of life</article-title><source>Am Rev Respir Dis</source><year>1987</year><volume>135</volume><fpage>1069</fpage><lpage>74</lpage><pub-id pub-id-type="pmid">3579005</pub-id></citation></ref><ref id="b20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hirano</surname><given-names>T</given-names></name><name><surname>Yamagata</surname><given-names>T</given-names></name><name><surname>Gohda</surname><given-names>M</given-names></name><etal></etal></person-group><article-title>Inhibition of reactive nitrogen species production in COPD airways: comparison of inhaled corticosteroid and oral theophylline</article-title><source>Thorax</source><year>2006</year><volume>61</volume><fpage>761</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">16936236</pub-id></citation></ref><ref id="b21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hirata</surname><given-names>K</given-names></name><name><surname>Nishimura</surname><given-names>M</given-names></name><name><surname>Ichinose</surname><given-names>M</given-names></name><etal></etal></person-group><article-title>Tiotropium once daily improves health status in Japanese patients with COPD</article-title><source>Am J Respir Crit Care Med</source><year>2003</year><volume>167</volume><fpage>A94</fpage></citation></ref><ref id="b22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ichinose</surname><given-names>M</given-names></name><name><surname>Nishimura</surname><given-names>M</given-names></name><name><surname>Hirata</surname><given-names>K</given-names></name><etal></etal></person-group><article-title>Tiotropium once daily improves spirometry over 24 hours in Japanese patients with COPD</article-title><source>Am J Respir Crit Care Med</source><year>2003</year><volume>167</volume><fpage>A95</fpage></citation></ref><ref id="b23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ichinose</surname><given-names>M</given-names></name><name><surname>Fukuchi</surname><given-names>Y</given-names></name><name><surname>Nagai</surname><given-names>A</given-names></name><etal></etal></person-group><article-title>Large-scale telephone survey on burden of patients with chronic obstructive pulmonary disease (COPD) in Japan: confronting COPD</article-title><source>Respirology</source><year>2006</year><volume>11</volume><fpage>A154</fpage></citation></ref><ref id="b24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ito</surname><given-names>K</given-names></name><name><surname>Lim</surname><given-names>S</given-names></name><name><surname>Caramori</surname><given-names>G</given-names></name><etal></etal></person-group><article-title>A molecular mechanism of action of theophylline: Induction of histone deacetylase activity to decrease inflammatory gene expression</article-title><source>Proc Natl Acad Sci USA</source><year>2002</year><volume>99</volume><fpage>8921</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">12070353</pub-id></citation></ref><ref id="b25"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jackson</surname><given-names>RH</given-names></name><name><surname>McHenry</surname><given-names>JI</given-names></name><name><surname>Moreland</surname><given-names>FB</given-names></name><etal></etal></person-group><article-title>Clinical evaluation of elixophyllin with correlation of pulmonary function studies and theophylline serum levels in acute and chronic asthmatic patients</article-title><source>Dis Chest</source><year>1964</year><volume>45</volume><fpage>75</fpage><lpage>85</lpage><pub-id pub-id-type="pmid">14114639</pub-id></citation></ref><ref id="b26"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Karpel</surname><given-names>JP</given-names></name><name><surname>Kotch</surname><given-names>A</given-names></name><name><surname>Zinny</surname><given-names>M</given-names></name><etal></etal></person-group><article-title>A comparison of inhaled ipratropium, oral theophylline plus inhaled beta-agonist, and the combination of all three in patients with COPD</article-title><source>Chest</source><year>1994</year><volume>105</volume><fpage>1089</fpage><lpage>94</lpage><pub-id pub-id-type="pmid">8162730</pub-id></citation></ref><ref id="b27"><citation citation-type="book"><person-group person-group-type="author"><name><surname>Kelly</surname><given-names>HW</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Jenne</surname><given-names>JW</given-names></name><name><surname>Murphy</surname><given-names>S</given-names></name><name><surname>Dekker</surname><given-names>M</given-names></name></person-group><article-title>Theophylline toxicity</article-title><source>Drug therapy for asthma</source><year>1987</year><publisher-loc>New York</publisher-loc><fpage>925</fpage><lpage>51</lpage></citation></ref><ref id="b28"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kobayashi</surname><given-names>M</given-names></name><name><surname>Nasuhara</surname><given-names>Y</given-names></name><name><surname>Betsuyaku</surname><given-names>T</given-names></name><etal></etal></person-group><article-title>Effect of low-dose theophylline on airway inflammation in COPD</article-title><source>Respirology</source><year>2004</year><volume>9</volume><fpage>249</fpage><lpage>54</lpage><pub-id pub-id-type="pmid">15182277</pub-id></citation></ref><ref id="b29"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mitenko</surname><given-names>PA</given-names></name><name><surname>Ogilvie</surname><given-names>RI</given-names></name></person-group><article-title>Rational intravenous doses of theophylline</article-title><source>N Engl J Med</source><year>1973</year><volume>289</volume><fpage>600</fpage><lpage>3</lpage><pub-id pub-id-type="pmid">4723589</pub-id></citation></ref><ref id="b30"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Moor-Jankowski</surname><given-names>J</given-names></name></person-group><article-title>Primate animals for biomedical research evaluation by the British Medical Research Council Laboratory Animal Centre. A critical review</article-title><source>J Med Primatol</source><year>1976</year><volume>5</volume><fpage>365</fpage><lpage>71</lpage><pub-id pub-id-type="pmid">828933</pub-id></citation></ref><ref id="b31"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Murciano</surname><given-names>D</given-names></name><name><surname>Auclair</surname><given-names>MH</given-names></name><name><surname>Pariente</surname><given-names>R</given-names></name><etal></etal></person-group><article-title>A randomized, controlled trial of theophylline in patients with severe chronic obstructive pulmonary disease</article-title><source>N Engl J Med</source><year>1989</year><volume>320</volume><fpage>1521</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">2498658</pub-id></citation></ref><ref id="b32"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Niewoehner</surname><given-names>DE</given-names></name><name><surname>Rice</surname><given-names>K</given-names></name><name><surname>Cote</surname><given-names>C</given-names></name><etal></etal></person-group><article-title>Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial</article-title><source>Ann Intern Med</source><year>2005</year><volume>143</volume><fpage>317</fpage><lpage>26</lpage><pub-id pub-id-type="pmid">16144890</pub-id></citation></ref><ref id="b33"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>O’Donnell</surname><given-names>DE</given-names></name><name><surname>Fluge</surname><given-names>T</given-names></name><name><surname>Gerken</surname><given-names>F</given-names></name><etal></etal></person-group><article-title>Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD</article-title><source>Eur Respir J</source><year>2004</year><volume>23</volume><fpage>832</fpage><lpage>40</lpage><pub-id pub-id-type="pmid">15218994</pub-id></citation></ref><ref id="b34"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rodriguez-Roisin</surname><given-names>R</given-names></name></person-group><article-title>Toward a consensus definition for COPD exacerbations</article-title><source>Chest</source><year>2000</year><volume>117</volume><fpage>398S</fpage><lpage>401S</lpage><pub-id pub-id-type="pmid">10843984</pub-id></citation></ref><ref id="b35"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sullivan</surname><given-names>P</given-names></name><name><surname>Bekir</surname><given-names>S</given-names></name><name><surname>Jaffar</surname><given-names>Z</given-names></name><etal></etal></person-group><article-title>Anti-inflammatory effects of low-dose oral theophylline in atopic asthma</article-title><source>Lancet</source><year>1994</year><volume>343</volume><fpage>1006</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">7909049</pub-id></citation></ref><ref id="b36"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Thirstrup</surname><given-names>S</given-names></name></person-group><article-title>Control of airway smooth muscle tone: II-pharmacology of relaxation</article-title><source>Respir Med</source><year>2000</year><volume>94</volume><fpage>519</fpage><lpage>28</lpage><pub-id pub-id-type="pmid">10921754</pub-id></citation></ref><ref id="b37"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tsukino</surname><given-names>M</given-names></name><name><surname>Nishimura</surname><given-names>K</given-names></name><name><surname>Ikeda</surname><given-names>A</given-names></name><etal></etal></person-group><article-title>Effects of theophylline and ipratropium bromide on exercise performance in patients with stable chronic obstructive pulmonary disease</article-title><source>Thorax</source><year>1998</year><volume>53</volume><fpage>269</fpage><lpage>73</lpage><pub-id pub-id-type="pmid">9741369</pub-id></citation></ref><ref id="b38"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Turner-Warwick</surname><given-names>M</given-names></name></person-group><article-title>Study of theophylline plasma levels after oral administration of new theophylline compounds</article-title><source>Br Med J</source><year>1957</year><volume>2</volume><fpage>67</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">13436856</pub-id></citation></ref><ref id="b39"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>van Noord</surname><given-names>JA</given-names></name><name><surname>Aumann</surname><given-names>JL</given-names></name><name><surname>Janssens</surname><given-names>E</given-names></name><etal></etal></person-group><article-title>Effects of tiotropium with and without formoterol on airflow obstruction and resting hyperinflation in patients with COPD</article-title><source>Chest</source><year>2006</year><volume>129</volume><fpage>509</fpage><lpage>17</lpage><pub-id pub-id-type="pmid">16537846</pub-id></citation></ref><ref id="b40"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vincken</surname><given-names>W</given-names></name><name><surname>van Noord</surname><given-names>JA</given-names></name><name><surname>Greefhorst</surname><given-names>AP</given-names></name><etal></etal></person-group><article-title>Improved health outcomes in patients with COPD during 1 yr’s treatment with tiotropium</article-title><source>Eur Respir J</source><year>2002</year><volume>19</volume><fpage>209</fpage><lpage>16</lpage><pub-id pub-id-type="pmid">11871363</pub-id></citation></ref><ref id="b41"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>ZuWallack</surname><given-names>RL</given-names></name><name><surname>Mahler</surname><given-names>DA</given-names></name><name><surname>Reilly</surname><given-names>D</given-names></name><etal></etal></person-group><article-title>Salmeterol plus theophylline combination therapy in the treatment of COPD</article-title><source>Chest</source><year>2001</year><volume>119</volume><fpage>1661</fpage><lpage>70</lpage><pub-id pub-id-type="pmid">11399688</pub-id></citation></ref></ref-list><fn-group><fn id="fn2" fn-type="other"><label>*</label><p><bold>Appendix</bold></p></fn></fn-group></back></article>